AI Article Synopsis
- The study investigates the potential of killer yeasts and their toxins as a biological method for treating leishmaniasis, a widespread parasitic disease.
- Killer yeasts were isolated, and their toxins (K2 and K.L) showed significantly lower IC50 values against leishmaniasis-causing organisms compared to standard treatments like Glucantime and Amphotericin B.
- The research concludes that K2 and K.L toxins possess strong antileishmanial properties, presenting a promising alternative for biological treatment of leishmaniasis.
Article Abstract
Aim: Leishmaniasis is a globally prevalent parasitic disease that has drawn significant attention. Killer yeasts offer a novel biological control method, presenting a potential alternative for treating leishmaniasis. This study evaluates the antileishmanial activity of and killer toxins against .
Materials & Methods: Killer yeasts were isolated using the Well method. The genes encoding K2 and K.L killer toxins were identified by PCR, and the toxins were purified via SDS-PAGE. Antileishmanial and cytotoxic effects on promastigotes and amastigotes were evaluated using the MTT assay.
Results: The first killer isolate was identified as ZBAM (GenBank accession: OQ376749.1) and the second as ZBAM (GenBank accession: OQ401036.1). IC50 values of K2 and K.L toxins against promastigotes were significantly lower than Glucantime and Amphotericin B. The EC50 values at 24 hours for Glucantime, K2, and K.L were 11.83 ± 0.02 μg/ml, 2.35 ± 0.01 μg/ml, and 3.23 ± 0.03 μg/ml, respectively. The EC50 values for K2 and K.L against amastigotes were also lower than Glucantime.
Conclusion: This is the first report of the antileishmanial effects of K2 and K.L toxins against , suggesting these yeasts as promising candidates for biological leishmaniasis treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17460913.2024.2443329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Killer Toxin: From Origin to Biomedical Research.
Microorganisms
December 2024
Membrane Biophysics and Nanotechnology Laboratory, Natural Sciences Faculty, Autonomous University of Quéretaro, Av. De las Ciencias S/N, Juriquilla, Querétaro 76220, Mexico.
The systems of are defined by the co-infection of two viral agents, an M virus and a helper virus. Each toxin is determined by the type of M virus (ScV-M1, ScV-M2, ScV-M28, and ScV-Mlus), which encodes a specific toxin (K1, K2, K28, and Klus). Since their discovery, interest in their potential use as antimicrobial agents has driven research into the mechanisms of action of these toxins on susceptible cells.
View Article and Find Full Text PDFColey's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment.
Biomedicines
November 2024
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancer immunobiology is one of the hot topics of discussion amongst researchers today, and immunotherapeutic modalities are among the selected few emerging approaches to cancer treatment that have exhibited a promising outlook. However, immunotherapy is not a new kid on the block; it has been around for centuries. The origin of cancer immunotherapy in modern medicine can be traced back to the initial reports of spontaneous regression of malignant tumors in some patients following an acute febrile infection, at the turn of the twentieth century.
View Article and Find Full Text PDFZymocin-like killer toxin gene clusters in the nuclear genomes of filamentous fungi.
Fungal Genet Biol
January 2025
Conway Institute and School of Medicine, University College Dublin, Dublin 4, Ireland. Electronic address:
Zymocin-like killer toxins are anticodon nucleases secreted by some budding yeast species, which kill competitor yeasts by cleaving tRNA molecules. They are encoded by virus-like elements (VLEs), cytosolic linear DNA molecules that are also called killer plasmids. To date, toxins of this type have been found only in budding yeast species (Saccharomycotina).
View Article and Find Full Text PDFA novel inhibitory strategy of using and killer toxins.
Future Microbiol
December 2024
Department of Biology, Faculty of Biological Sciences, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.
Article Synopsis
- The study investigates the potential of killer yeasts and their toxins as a biological method for treating leishmaniasis, a widespread parasitic disease.
- Killer yeasts were isolated, and their toxins (K2 and K.L) showed significantly lower IC50 values against leishmaniasis-causing organisms compared to standard treatments like Glucantime and Amphotericin B.
- The research concludes that K2 and K.L toxins possess strong antileishmanial properties, presenting a promising alternative for biological treatment of leishmaniasis.
Diphtheria Toxoid-Derived T-Helper Epitope and α-galactosylceramide Synergistically Enhance the Immunogenicity of Glycopeptide Antigen.
ACS Pharmacol Transl Sci
December 2024
National Key Laboratory of Green Pesticide, International Joint Research Center for Intelligent Biosensing Technology and Health, College of Chemistry, Central China Normal University, Wuhan 430079, China.
The tumor-associated antigen MUC1 is an attractive target for immunotherapy, however, its weak immunogenicity limits the induction of antitumor immune responses. To overcome this limitation, in this study, MUC1 glycopeptide was covalently linked with a diphtheria toxin-derived T-helper epitope (DT). Subsequently, the resulting DT-MUC1 glycopeptide was physically mixed with natural killer T cell agonist αGalCer to explore their immunomodulatory synergy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!